Table 2. Intention-to-Treat Rates of Completion.
| Outcome | No./total No. (%) | |||
|---|---|---|---|---|
| Standard message | Tailored message | Control group | Total | |
| WCC scheduled within 2 wk | 58/315 (18.4) | 47/315 (14.9) | 30/315 (9.5) | 135/945 (14.3) |
| WCC completed within 8 wk | 76/315 (24.1) | 61/315 (19.4) | 40/315 (12.7) | 177/945 (18.7) |
| Receipt of COVID vaccination within 8 wka | 14/84 (16.7) | 4/83 (4.8) | 3/82 (3.7) | 21/249 (8.4) |
| Receipt of DTaP within 8 wka | 6/32 (30.0) | 6/34 (30.0) | 8/32 (40.0) | 20/98 (20.4) |
| Receipt of HPV within 8 wka | 13/49 (44.8) | 9/52 (31.0) | 7/50 (24.1) | 29/151 (19.2) |
| Receipt of MCV4 within 8 wka | 10/54 (32.3) | 12/57 (38.7) | 9/49 (29.0) | 31/160 (19.4) |
Abbreviations: HPV, human papillomavirus vaccine; MCV4, meningococcal conjugate vaccine; DTaP, diphtheria and tetanus toxoids and acellular pertussis; WCC, well child care.
a
Analysis includes all patients eligible to receive this vaccine during the 8-week study period.